Biologics Safety Testing Market Size, Share, Growth Analysis, By Test(Endotoxin Test, Sterility Test, Adventitious Agent Detection Test, and Others), By Application(Blood & Blood-based Products, Vaccines & Therapeutics, Stem Cells, and Others), By End-use(Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Companies, Research and Academia, and Others), By Region - Industry Forecast 2024-2031

Q: What is the global market size of Biologics Safety Testing Market?

Global Biologics Safety Testing Market size was valued at USD 4.70 billion in 2022 and is poised to grow from USD 5.25 billion in 2023 to USD 12.72 billion by 2031, growing at a CAGR of 11.70% during the forecast period (2024-2031).

Q: Who are the key vendors in the Global Biologics Safety Testing Market?

The Global Biologics Safety Testing Market showcases a competitive landscape characterised by a diverse mix of well-established brands, emerging players, and specialised producers. In this dynamic environment, innovation serves as a pivotal competitive edge. Leading brands dedicate significant resources to research and development endeavours, consistently introducing fresh flavours, innovative packaging formats, and health-focused variations in response to ever-evolving consumer preferences. 'Cytovance Biologics', 'Eurofins Scientific', 'Merck KGaA', 'Biomerieux SA', 'Lonza', 'Promega Corporation', 'Thermo Fisher Scientific', 'WuXi AppTec', 'Nelson Laboratories, LLC', 'Almac Group', 'GenScript', 'InvivoGen', 'Toxikon', 'Maravai LifeSciences'

Q: What is the key market trend for Global Biologics Safety Testing Market?

Global regulatory bodies have embarked on a path of heightened vigilance over biopharmaceutical products, prioritising both patient safety and product quality. These stringent regulations mandate an exhaustive spectrum of safety evaluations, elevating biological safety testing to a cornerstone in the landscape of drug approvals. For pharmaceutical and biotech enterprises, strict adherence to these evolving standards isn't just a necessity but a crucial pathway to securing product approval and market entry. This escalating emphasis on compliance fuels an increased demand for testing services, firmly cementing the pivotal role of biological safety testing within this framework.

Report ID: SQMIG35A2786 | Region: Global | Published Date: July, 1990
Pages: 219 | Tables: 93 | Figures: 70

Biologics Safety Testing Market News

In May 2022, Avance Biosciences achieved a noteworthy milestone by completing a substantial expansion, acquiring an expansive 26,000 square feet of laboratory space. This strategic move serves as a catalyst, empowering Avance to diversify its service portfolio offered to biopharmaceutical and CDMO clients. The newly established facilities are specifically tailored to augment protein and cell-based assay services, emphasising the enhancement of protein analysis capabilities. These expanded services encompass a comprehensive range, spanning ELISA assays, protein characterization, and immunoassays, strategically catering to the evolving requirements of their clientele.

In September 2023, Pace Analytical Services introduced a groundbreaking PFAS test method designed to revolutionise testing efficacy. Known as ASTM D8421/EPA 8327, this method leverages isotope dilution and LC/MS/MS technology to meticulously analyse up to 44 PFAS compounds in both aqueous and solid samples. This innovative approach offers several advantages, including accelerated delivery of results, reduced sample size requirements, and the assurance of precise quantification. By enabling expedited and cost-effective analyses while ensuring accuracy in identifying PFAS compounds, this method signifies a significant advancement in environmental testing methodologies, promising a notable leap forward in the landscape of environmental analysis and safety protocols.

Biologics Safety Testing Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Biologics Safety Testing Market size was valued at USD 4.70 billion in 2022 and is poised to grow from USD 5.25 billion in 2023 to USD 12.72 billion by 2031, growing at a CAGR of 11.70% during the forecast period (2024-2031).

The Biologics Safety Testing Market showcases a competitive landscape characterised by a diverse mix of well-established brands, emerging players, and specialised producers. In this dynamic environment, innovation serves as a pivotal competitive edge. Leading brands dedicate significant resources to research and development endeavours, consistently introducing fresh flavours, innovative packaging formats, and health-focused variations in response to ever-evolving consumer preferences. 'Cytovance Biologics', 'Eurofins Scientific', 'Merck KGaA', 'Biomerieux SA', 'Lonza', 'Promega Corporation', 'Thermo Fisher Scientific', 'WuXi AppTec', 'Nelson Laboratories, LLC', 'Almac Group', 'GenScript', 'InvivoGen', 'Toxikon', 'Maravai LifeSciences'

The expansions witnessed in the pharmaceutical and biotechnology sectors, propelled by substantial investments in research and development, signify a pivotal epoch in healthcare progress. These industries stand at the forefront of creating pharmaceuticals, biologics, and vaccines, actively addressing the complexities associated with diverse healthcare challenges, especially in combating intricate diseases. This surge in innovation inevitably leads to an increased necessity for stringent safety evaluations, wherein biological safety testing plays a pivotal role in safeguarding patient well-being.

regulatory bodies have embarked on a path of heightened vigilance over biopharmaceutical products, prioritising both patient safety and product quality. These stringent regulations mandate an exhaustive spectrum of safety evaluations, elevating biological safety testing to a cornerstone in the landscape of drug approvals. For pharmaceutical and biotech enterprises, strict adherence to these evolving standards isn't just a necessity but a crucial pathway to securing product approval and market entry. This escalating emphasis on compliance fuels an increased demand for testing services, firmly cementing the pivotal role of biological safety testing within this framework.

North America emerges as the leader in shaping and propelling the market dynamics, poised to sustain its influential trajectory in the forecast period. This regional dominance is attributed to various key factors, notably the robust presence of a multitude of biotechnology and pharmaceutical companies. Renowned for its status as an innovation hub, North America consistently fosters the evolution of cutting-edge technologies, driving advancements and breakthroughs within the industry.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Biologics Safety Testing Market News

Biologics Safety Testing Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Biologics Safety Testing Market?

Who are the key vendors in the Biologics Safety Testing Market?

What is the key driver of Biologics Safety Testing Market?

What is the key market trend for Biologics Safety Testing Market?

Which region accounted for the largest share in Biologics Safety Testing Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300